

21<sup>st</sup> July, 2025

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Acquisition of securities in iCaltech Innovations Private Limited**

Dear Sir/Madam,

Pursuant to the provisions of the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Company has entered into definitive agreements to acquire 20% voting rights in iCaltech Innovations Private Limited.

The details required to be disclosed under the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November, 2024 on the captioned subject are enclosed to this intimation as Annexure I.

A copy of press release for the said investment is enclosed as Annexure II.

Please take the above information on record.

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Mandar Kurghode

**Annexure - I**

Details as per the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	<p><b>Name of the target entity:</b> iCaltech Innovations Private Limited (“iCaltech”)</p> <p><b>Brief Details:</b> iCaltech headquartered in Bangalore, India, is engaged in the conceptualisation, development, manufacturing and marketing of regulatory approved medical diagnostic products (primarily in respiratory).</p> <p><b>Turnover:</b> Refer point (j)</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>Acquisition doesn’t fall within the purview of related party transactions.</p> <p>None of the promoter / promoter group / group companies have any interest in the entity.</p>
c)	Industry to which the entity being acquired belongs	Healthcare, Medical equipment & Diagnostics (primarily in respiratory)
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Through this collaboration, Cipla aims to strengthen its partnership with iCaltech for developing integrated healthcare solutions and leveraging synergies between pharmaceutical expertise and advanced medical device technologies.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f)	Indicative time-period for completion of the acquisition	The investment is expected to be completed within 1 month from the date of the signing of the transaction documents, or by such other date as maybe mutually agreed between the parties.

g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
h)	Cost of acquisition or the price at which the shares are acquired	Approx. INR 5 crore towards the acquisition of 20% voting rights through subscription of: i. 1,50,820 optionally convertible preference shares of face value of INR 10 each; and ii. 1 equity share of face value of INR 10 each.
i)	Percentage of shareholding / control acquired and / or number of shares acquired	
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p><b>Brief Background:</b> Refer (a) above.</p> <p><b>History of last 3 years turnover:</b></p> <p>FY 2024-25: INR 6.70 crores  FY 2023-24: INR 4.19 crores  FY 2022-23: INR 1.28 crores</p> <p><b>Date of Incorporation:</b> 10<sup>th</sup> June, 2016</p> <p><b>Country of presence:</b> India</p>

**Cipla Ltd.**

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 F +91 22 41916120 W [www.cipla.com](http://www.cipla.com) E-mail [contactus@cipla.com](mailto:contactus@cipla.com) Corporate Identity Number L24239MH1935PLC002380

## **Cipla announces investment in iCaltech Innovations to strengthen respiratory play**

*Deepens commitment to enhance access to advanced respiratory diagnostic solutions*

**Mumbai, July 21, 2025:** Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has signed definitive agreements for investment in Optionally Convertible Preference Shares of iCaltech Innovations Private Limited (hereafter referred to as "iCaltech"), subject to completion of certain conditions. iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core focus on respiratory care.

Commenting on the development, **Mr. Achin Gupta, Global COO, Cipla Limited** said, "As lung leaders, our decision to invest in iCaltech reflects Cipla's commitment to advancing respiratory diagnostics. With the aim to reduce the existing gap in the current ecosystem, our strategic funding will enable iCaltech to further expand and develop innovative devices. We remain committed towards providing easy access to high-quality diagnostic solutions across India."

Strategic partnerships remain central to Cipla's innovation engine, as the company continues to expand its digital, devices and diagnostics offerings and build on its legacy of lung leadership.

\*\*\*

### **About iCaltech**

iCaltech is a Bangalore based ISO 13485 certified Medical Devices Company. iCaltech conceptualises, develops, manufactures and markets Regulatory approved Medical Diagnostic Products. iCaltech aims to bring ease of access to respiratory diagnostics tests, leading to early detection and treatment, through its innovative solutions, cutting-edge research and deep expertise.

### **About Cipla**

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets. Cipla is ranked 3<sup>rd</sup> largest in pharma in India (IQVIA MAT Mar'25), 2<sup>nd</sup> largest in the pharma prescription market in South Africa (IQVIA MAT Feb'25), and 4<sup>th</sup> largest by prescription for Generic inhalation products in the US Gx (IQVIA TRx MAT Mar'25). For almost nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. For more, please visit [www.cipla.com](http://www.cipla.com), or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

### **Media Contacts:**

Corporate Communications

Heena Kanal

E-Mail: [CorpComm@cipla.com](mailto:CorpComm@cipla.com)

Investor Relations

Diksha Maheshwari

E-Mail: [Investor.Relations@cipla.com](mailto:Investor.Relations@cipla.com)